Reported Earlier, Vertex Wins FDA Approval Expanding CASGEVY Use To Children As Young As 2 With Severe Sickle Cell Disease Or Beta Thalassemia
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated VRTX | 0.00 |
- First and only approved genetic therapy to treat children as young as 2 years for both severe sickle cell disease and transfusion-dependent beta thalassemia -
- Approximately 5,500 additional children in the U.S. are now eligible for this established one-time therapy, expanding upon the prior FDA approval in people 12 years and older -
- Regulatory review for label expansion underway in the Kingdom of Saudi Arabia and United Kingdom